2023
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362DOI: 10.1093/jac/dkad362
Morris, S., Long, M., Savage, A., Owen, A., Rannard, S., & Cauldbeck, H. (n.d.). Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration. Nanoscale Advances. doi:10.1039/d3na00454fDOI: 10.1039/d3na00454f
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine. (Journal article)
Liu, C., Hern, F. Y., Shakil, A., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2023). Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.. Journal of materials chemistry. B. doi:10.1039/d3tb02268dDOI: 10.1039/d3tb02268d
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.. Viruses, 15(11), 2161. doi:10.3390/v15112161DOI: 10.3390/v15112161
Balta, V. A., Stiffler, D., Sayeed, A., Tripathi, A. K., Elahi, R., Mlambo, G., . . . Shapiro, T. A. (2023). Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.. Nature communications, 14(1), 6415. doi:10.1038/s41467-023-42030-xDOI: 10.1038/s41467-023-42030-x
Scarsi, K. K., Sayles, H., Kapungu, K., Sifuna, P., Ippolito, M. M., Furl, R., . . . Swindells, S. (2023). Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention.. The American journal of tropical medicine and hygiene, 109(4), 752-760. doi:10.4269/ajtmh.23-0245DOI: 10.4269/ajtmh.23-0245
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744DOI: 10.3390/v15081744
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823DOI: 10.1016/j.jchromb.2023.123823
De Neck, S., Penrice-Randal, R., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., . . . Kipar, A. (2023). The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses, 15(8), 1637. doi:10.3390/v15081637DOI: 10.3390/v15081637
Chang, Y. S., Li, S. -Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S. P., . . . Ammerman, N. C. (2023). Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 67(7). doi:10.1128/aac.00481-23DOI: 10.1128/aac.00481-23
Niezabitowska, E., Gray, D. M. M., Gallardo-Toledo, E., Owen, A., Rannard, S. P. P., & McDonald, T. O. O. (2023). Understanding the Degradation of Core-Shell Nanogels Using Asymmetrical Flow Field Flow Fractionation. JOURNAL OF FUNCTIONAL BIOMATERIALS, 14(7). doi:10.3390/jfb14070346DOI: 10.3390/jfb14070346
Obradovic, B., Roberts, O., Owen, A., Milosevic, I., Milic, N., Ranin, J., & Dragovic, G. (2023). Expression of CYP2B6 Enzyme in Human Liver Tissue of HIV and HCV Patients. MEDICINA-LITHUANIA, 59(7). doi:10.3390/medicina59071207DOI: 10.3390/medicina59071207
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835DOI: 10.3390/pharmaceutics15071835
Gaynor, K. U. U., Vaysburd, M., Harman, M. A. J., Albecka, A., Jeffrey, P., Beswick, P., . . . James, L. C. C. (2023). Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-39158-1DOI: 10.1038/s41467-023-39158-1
Elbaz, N. M., Tatham, L. M., Owen, A., Rannard, S., & McDonald, T. O. (2023). Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery. Food Hydrocolloids, 108908. doi:10.1016/j.foodhyd.2023.108908DOI: 10.1016/j.foodhyd.2023.108908
Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022) (Journal article)
Smith, T. A., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2023). Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022). TRIALS, 24(1). doi:10.1186/s13063-023-07364-3DOI: 10.1186/s13063-023-07364-3
Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy. (Preprint)
DOI: 10.1101/2023.04.12.536604
BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2DOI: 10.1186/s12981-023-00514-2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. (Preprint)
DOI: 10.1101/2022.01.23.477397
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0DOI: 10.1038/s41586-022-05594-0
Cirrincione, L. R., Nakalema, S., Chappell, C. A., Byakika-Kibwika, P., Kyohairwe, I., Winchester, L., . . . Scarsi, K. K. (2023). Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.. Contraception, 109975. doi:10.1016/j.contraception.2023.109975DOI: 10.1016/j.contraception.2023.109975
Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes. (Journal article)
Balta, V. A., Stiffler, D., Sayeed, A., Tripathi, A. K., Elahi, R., Mlambo, G., . . . Shapiro, T. A. (2023). Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes.. bioRxiv. doi:10.1101/2023.02.07.527535DOI: 10.1101/2023.02.07.527535
Chasing COVID-19 chemotherapeutics without putting the cart before the horse (Journal article)
Rannard, S. P., McDonald, T. O., & Owen, A. (2023). Chasing COVID-19 chemotherapeutics without putting the cart before the horse. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 89(1), 421-423. doi:10.1111/bcp.14575DOI: 10.1111/bcp.14575
Gurjar, R., Dickinson, L., Carr, D., Stohr, W., Bonora, S., Owen, A., . . . Boffito, M. (2022). Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. PHARMACOGENOMICS JOURNAL. doi:10.1038/s41397-022-00293-5DOI: 10.1038/s41397-022-00293-5
2022
Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K. K., Charoenpong, L., . . . Chokephaibulkit, K. (2022). Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. EMERGING MICROBES & INFECTIONS, 11(1), 2197-2206. doi:10.1080/22221751.2022.2117092DOI: 10.1080/22221751.2022.2117092
WHO Living Guidelines on antivirals for COVID-19 are evidence-based (Journal article)
Owen, A., Diaz, J. V., Guyatt, G., Lamontagne, F., Stegemann, M., Vandvik, P. O., & Agoritsas, T. (2022). WHO Living Guidelines on antivirals for COVID-19 are evidence-based. LANCET, 400(10369), 2196-2198. doi:10.1016/S0140-6736(22)02306-6DOI: 10.1016/S0140-6736(22)02306-6
Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., . . . Venter, W. D. F. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBIOMEDICINE, 86. doi:10.1016/j.ebiom.2022.104322DOI: 10.1016/j.ebiom.2022.104322
Neary, M., Owen, A., & Olagunju, A. (2022). A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm. Clinical Infectious Diseases, 75(Supplement_4), S490-S497. doi:10.1093/cid/ciac685DOI: 10.1093/cid/ciac685
Ammerman, N. C., Nuermberger, E. L., Owen, A., Rannard, S. P., Meyers, C. F., & Swindells, S. (2022). Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment. CLINICAL INFECTIOUS DISEASES, 75, S510-S516. doi:10.1093/cid/ciac672DOI: 10.1093/cid/ciac672
Prospects for Long-Acting Treatments for Hepatitis C (Journal article)
Thomas, D. L., Owen, A., & Kiser, J. J. (2022). Prospects for Long-Acting Treatments for Hepatitis C. CLINICAL INFECTIOUS DISEASES, 75, S525-S529. doi:10.1093/cid/ciac715DOI: 10.1093/cid/ciac715
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases (Journal article)
Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. (2022). The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. CLINICAL INFECTIOUS DISEASES, 75, S502-S509. doi:10.1093/cid/ciac750DOI: 10.1093/cid/ciac750
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants (Journal article)
Hentzien, M., Owen, A., Strub-Wourgaft, N., Perez-Casas, C., Troseid, M., & Calmy, A. (2022). Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. FRONTIERS IN MICROBIOLOGY, 13. doi:10.3389/fmicb.2022.998287DOI: 10.3389/fmicb.2022.998287
Sokhela, S., Bosch, B., Hill, A., Simmons, B., Woods, J., Johnstone, H., . . . Venter, W. D. F. (2022). Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(10), 2706-2712. doi:10.1093/jac/dkac266DOI: 10.1093/jac/dkac266
Fowotade, A., Bamidele, F., Egbetola, B., Fagbamigbe, A. F., Adeagbo, B. A., Adefuye, B. O., . . . Olagunju, A. (2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. FRONTIERS IN MEDICINE, 9. doi:10.3389/fmed.2022.956123DOI: 10.3389/fmed.2022.956123
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments (Journal article)
Weld, E. D., Astemborski, J., Kirk, G. D., Sulkowski, M. S., Katz, S., Rothman, R., . . . Thomas, D. L. (2022). Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. CLINICAL INFECTIOUS DISEASES, 75(1), 3-10. doi:10.1093/cid/ciab913DOI: 10.1093/cid/ciab913
Assmus, F., Driouich, J. -S., Abdelnabi, R., Vangeel, L., Touret, F., Adehin, A., . . . Chatelain, E. (2022). Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. MICROORGANISMS, 10(8). doi:10.3390/microorganisms10081639DOI: 10.3390/microorganisms10081639
Smith, T., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2022). Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). TRIALS, 23(1). doi:10.1186/s13063-022-06533-0DOI: 10.1186/s13063-022-06533-0
Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3DOI: 10.1186/s12981-022-00462-3
Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825dDOI: 10.1039/d2tb00825d
Seehusen, F., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., Subramaniam, K., . . . Kipar, A. (2022). Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. VIRUSES-BASEL, 14(5). doi:10.3390/v14051020DOI: 10.3390/v14051020
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays. (Preprint)
DOI: 10.1101/2022.03.03.482788
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463DOI: 10.1002/cpt.2463
Jeffreys, L. N., Pennington, S. H., Duggan, J., Caygill, C. H., Lopeman, R. C., Breen, A. F., . . . Biagini, G. A. (2022). Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 59(3). doi:10.1016/j.ijantimicag.2022.106542DOI: 10.1016/j.ijantimicag.2022.106542
Sacramento, C. Q., Fintelman-Rodrigues, N., Dias, S. S. G., Temerozo, J. R., Da Silva, A. D. P. D., da Silva, C. S., . . . Souza, T. M. L. (2022). Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. VIRUSES-BASEL, 14(2). doi:10.3390/v14020374DOI: 10.3390/v14020374
Quinn, T. M., Gaughan, E. E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., . . . Dhaliwal, K. (2022). Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBIOMEDICINE, 76. doi:10.1016/j.ebiom.2022.103856DOI: 10.1016/j.ebiom.2022.103856
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry (Preprint)
DOI: 10.12688/wellcomeopenres.17202.3
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2DOI: 10.12688/wellcomeopenres.17202.2
2021
Chandiwana, N. C., Serenata, C. M., Owen, A., Rannard, S., Casas, C. P., Scott, C., . . . Flexner, C. (2021). Impact of long-acting therapies on the global HIV epidemic. AIDS, 35, S137-S143. doi:10.1097/QAD.0000000000003102DOI: 10.1097/QAD.0000000000003102
Elbaz, N. M., Tatham, L. M., Owen, A., Rannard, S., & McDonald, T. O. (2021). Redispersible nanosuspensions as a plausible oral delivery system for curcumin. Food Hydrocolloids, 121, 107005. doi:10.1016/j.foodhyd.2021.107005DOI: 10.1016/j.foodhyd.2021.107005
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318DOI: 10.1093/jac/dkab318
Brain, D., Plant-Hately, A., Heaton, B., Arshad, U., David, C., Hedrich, C., . . . Liptrott, N. J. (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. ADVANCED DRUG DELIVERY REVIEWS, 178. doi:10.1016/j.addr.2021.113848DOI: 10.1016/j.addr.2021.113848
Roberts, O., Kinvig, H., Owen, A., Lamorde, M., Siccardi, M., & Scarsi, K. K. (2021). In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV MEDICINE, 22(10), 898-906. doi:10.1111/hiv.13136DOI: 10.1111/hiv.13136
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1DOI: 10.12688/wellcomeopenres.17202.1
Huo, J., Mikolajek, H., Le Bas, A., Clark, J. J., Sharma, P., Kipar, A., . . . Moynie, L. (2021). A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-25480-zDOI: 10.1038/s41467-021-25480-z
Salzer, R., Clark, J. J., Vaysburd, M., Chang, V. T., Albecka, A., Kiss, L., . . . Lowe, J. (2021). Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. FEBS LETTERS, 595(18), 2323-2340. doi:10.1002/1873-3468.14171DOI: 10.1002/1873-3468.14171
Hiscox, J. A., Khoo, S. H., Stewart, J. P., & Owen, A. (2021). Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2230-2233. doi:10.1093/jac/dkab189DOI: 10.1093/jac/dkab189
Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4DOI: 10.1186/s13063-021-05458-4
David, C. A. W., del Castillo Busto, M. E., Cuello-Nunez, S., Goenaga-Infante, H., Barrow, M., Fernig, D. G., . . . Liptrott, N. J. (2021). Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles. CELL AND BIOSCIENCE, 11(1). doi:10.1186/s13578-021-00648-8DOI: 10.1186/s13578-021-00648-8
Pertinez, H., Rajoli, R. K. R., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2121-2128. doi:10.1093/jac/dkab135DOI: 10.1093/jac/dkab135
Boffito, M., Back, D. J., Flexner, C., Sjo, P., Blaschke, T. F., Horby, P. W., . . . Owen, A. (2021). Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(1), 64-68. doi:10.1002/cpt.2099DOI: 10.1002/cpt.2099
Sacramento, C. Q., Fintelman-Rodrigues, N., Temerozo, J. R., Dias Da Silva, A. D. P., Gomes Dias, S. D. S., da Silva, C. D. S., . . . Souza, T. M. L. (2021). <i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(7), 1874-1885. doi:10.1093/jac/dkab072DOI: 10.1093/jac/dkab072
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? (Journal article)
Stachulski, A. V., Taujanskas, J., Pate, S. L., Rajoli, R. K. R., Aljayyoussi, G., Pennington, S. H., . . . O'Neill, P. M. (2021). Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS INFECTIOUS DISEASES, 7(6), 1317-1331. doi:10.1021/acsinfecdis.0c00478DOI: 10.1021/acsinfecdis.0c00478
Nwogu, J. N., Gandhi, M., Owen, A., Khoo, S., Taiwo, B., Olagunju, A., . . . Babalola, C. P. (2021). Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.. AIDS (London, England). doi:10.1097/qad.0000000000002984DOI: 10.1097/qad.0000000000002984
Salzer, R., Clark, J., Vaysburd, M., Chang, V., Albecka, A., Kiss, L., . . . Löwe, J. (2021). Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. doi:10.1101/2021.05.18.444622DOI: 10.1101/2021.05.18.444622
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
A living WHO guideline on drugs to prevent covid-19 (Journal article)
Lamontagne, F., Agoritsas, T., Siemieniuk, R., Rochwerg, B., Bartoszko, J., Askie, L., . . . Jacobs, M. (2021). A living WHO guideline on drugs to prevent covid-19. BMJ-BRITISH MEDICAL JOURNAL, 372. doi:10.1136/bmj.n526DOI: 10.1136/bmj.n526
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Neary, M., . . . Owen, A. (2021). Optimisation and validation of a sensitive bioanalytical method for niclosamide. doi:10.1101/2021.01.13.426426DOI: 10.1101/2021.01.13.426426
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. (Journal article)
Pertinez, H., Rajoli, R. K., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.. medRxiv. doi:10.1101/2021.01.03.21249159DOI: 10.1101/2021.01.03.21249159
Olagunju, A., Fowotade, A., Olagunoye, A., Ojo, T. O., Adefuye, B. O., Fagbamigbe, A. F., . . . Owen, A. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 22(1). doi:10.1186/s13063-020-04987-8DOI: 10.1186/s13063-020-04987-8
Long-acting drugs and formulations for the treatment and prevention of HIV infection (Journal article)
Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(1). doi:10.1016/j.ijantimicag.2020.106220DOI: 10.1016/j.ijantimicag.2020.106220
Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events (Conference Paper)
Hoffmann, C., MacKay, A., Schewe, C. K., Hansen, S., Buhk, T., Fenske, S., . . . Elliot, E. (2021). Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events. In INFECTION Vol. 49 (pp. S21-S22). Retrieved from https://www.webofscience.com/
2020
Rogers, H. E., Chambon, P., Flynn, S., Hern, F. Y., Owen, A., & Rannard, S. P. (2020). Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates. NANOSCALE ADVANCES, 2(11), 5468-5477. doi:10.1039/d0na00696cDOI: 10.1039/d0na00696c
Elkateb, H., Tatham, L. M., Cauldbeck, H., Niezabitowska, E., Owen, A., Rannard, S., & McDonald, T. (n.d.). Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV. International Journal of Pharmaceutics, 119794. doi:10.1016/j.ijpharm.2020.119794DOI: 10.1016/j.ijpharm.2020.119794
Safety perspectives on presently considered drugs for the treatment of COVID‐19 (Journal article)
Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (n.d.). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204DOI: 10.1111/bph.15204
A living WHO guideline on drugs for covid-19 (Journal article)
Agarwal, A., Hunt, B., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., . . . Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ (Clinical research ed.), 370, m3379. doi:10.1136/bmj.m3379DOI: 10.1136/bmj.m3379
David, C. A. W., Barrow, M., Murray, P., Rosseinsky, M. J., Owen, A., & Liptrott, N. J. (n.d.). In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. International Journal of Molecular Sciences, 21(16), 5610. doi:10.3390/ijms21165610DOI: 10.3390/ijms21165610
Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients (Journal article)
Dragovic, G., Dimitrijevic, B., Kusic, J., Soldatovic, I., Jevtovic, D., Olagunju, A., & Owen, A. (2020). Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(7), 1289-1295. doi:10.1111/bcp.14230DOI: 10.1111/bcp.14230
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz (Journal article)
Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.0000000000000401DOI: 10.1097/FPC.0000000000000401
Pharmacokinetics of HIV therapies in pregnant patients: an update (Journal article)
Neary, M., Owen, A., & Olagunju, A. (2020). Pharmacokinetics of HIV therapies in pregnant patients: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 16(6), 449-461. doi:10.1080/17425255.2020.1754792DOI: 10.1080/17425255.2020.1754792
Hobson, J. J., Rannard, S. P., Owen, A., & Liptrott, N. J. (2020). Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity. Nanomedicine. doi:10.2217/nnm-2019-0447DOI: 10.2217/nnm-2019-0447
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C., Owen, A., & Siccardi, M. (2020). Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00155-20DOI: 10.1128/aac.00155-20
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1101/2020.05.01.20087130
Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population (Journal article)
Neary, M., Olagunju, A., Sarfo, F., Phillips, R., Moss, D., Owen, A., & Chadwick, D. (2020). Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1267-1271. doi:10.1093/jac/dkaa008DOI: 10.1093/jac/dkaa008
Elliot, E. R., Neary, M., Else, L., Khoo, S., Moyle, G., Carr, D. F., . . . Owen, A. (2020). Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1259-1266. doi:10.1093/jac/dkz558DOI: 10.1093/jac/dkz558
Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (2020). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. JOURNAL OF VIRUS ERADICATION, 6(2), 52-60. Retrieved from https://www.webofscience.com/
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379DOI: 10.1101/2020.04.16.20068379
Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-lsoniazid Pharmacokinetics during Antituberculosis Treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(4). doi:10.1128/AAC.02376-49DOI: 10.1128/AAC.02376-49
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). <i>CYP2B6</i>*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. JOURNAL OF CLINICAL PHARMACOLOGY, 60(3), 351-360. doi:10.1002/jcph.1527DOI: 10.1002/jcph.1527
Arshad, U., Sutton, P. A., Ashford, M. B., Treacher, K. E., Liptrott, N. J., Rannard, S. P., . . . Owen, A. (2020). Critical considerations for targeting colorectal liver metastases with nanotechnology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 12(2). doi:10.1002/wnan.1588DOI: 10.1002/wnan.1588
Dickinson, L., Gurjar, R., Stoehr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Boffito, M. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 628-639. doi:10.1093/jac/dkz479DOI: 10.1093/jac/dkz479
Bunglawala, F., Rajoli, R. K. R., Mirochnick, M., Owen, A., & Siccardi, M. (2020). Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 640-647. doi:10.1093/jac/dkz506DOI: 10.1093/jac/dkz506
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19DOI: 10.1128/AAC.00947-19
Elbaz, N. M., Owen, A., Rannard, S., & McDonald, T. O. (2020). Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 574. doi:10.1016/j.ijpharm.2019.118866DOI: 10.1016/j.ijpharm.2019.118866
N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment. (Journal article)
Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02376-19DOI: 10.1128/aac.02376-19
HIV, ART and COVID-19: interplay and interactions (Conference Paper)
Sabin, C., Waters, L., Sparrowhawk, A., Owen, A., & Cevik, M. (2020). HIV, ART and COVID-19: interplay and interactions. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 23 (pp. 13). Retrieved from https://www.webofscience.com/
2019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies (Journal article)
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068DOI: 10.1016/j.ejps.2019.105068
Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529cDOI: 10.1039/c9na00529c
Ayuso, P., Neary, M., Chiong, J., & Owen, A. (2019). Meta-analysis of the effect of <i>CYP2B6, CYP2A6, UGT2B7</i> and <i>CAR</i> polymorphisms on efavirenz plasma concentrations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(11), 3281-3290. doi:10.1093/jac/dkz329DOI: 10.1093/jac/dkz329
Rajoli, R. K. R., Flexner, C., Chiong, J., Owen, A., Donnelly, R. F., Larraneta, E., & Siccardi, M. (2019). Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 144, 101-109. doi:10.1016/j.ejpb.2019.09.011DOI: 10.1016/j.ejpb.2019.09.011
Neary, M., Chappell, C. A., Scarsi, K. K., Nakalema, S., Matovu, J., Achilles, S. L., . . . Lamorde, M. (2019). Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(10), 3003-3010. doi:10.1093/jac/dkz298DOI: 10.1093/jac/dkz298
On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019) (Journal article)
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(9), 902. doi:10.1038/s41565-019-0538-3DOI: 10.1038/s41565-019-0538-3
On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019) (Journal article)
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(8), 811. doi:10.1038/s41565-019-0523-xDOI: 10.1038/s41565-019-0523-x
Tatham, L. M., Liptrott, N. J., Rannard, S. P., & Owen, A. (2019). Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. MOLECULES, 24(15). doi:10.3390/molecules24152685DOI: 10.3390/molecules24152685
On the issue of transparency and reproducibility in nanomedicine (Journal article)
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine. NATURE NANOTECHNOLOGY, 14(7), 629-635. doi:10.1038/s41565-019-0496-9DOI: 10.1038/s41565-019-0496-9
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide (Journal article)
Cerrone, M., Alfarisi, O., Neary, M., Marzinke, M. A., Parsons, T. L., Owen, A., . . . Boffito, M. (2019). Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1670-1678. doi:10.1093/jac/dkz068DOI: 10.1093/jac/dkz068
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726DOI: 10.1093/infdis/jiy726
Savage, A. C., Tatham, L. M., Siccardi, M., Scott, T., Vourvahis, M., Clark, A., . . . Owen, A. (2019). Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 30-36. doi:10.1016/j.ejpb.2018.05.015DOI: 10.1016/j.ejpb.2018.05.015
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571DOI: 10.1093/jac/dky571
Tatham, L. M., Savage, A. C., Dwyer, A., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2019). Towards a Maraviroc long-acting injectable nanoformulation. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 92-98. doi:10.1016/j.ejpb.2018.04.009DOI: 10.1016/j.ejpb.2018.04.009
Francis, J., Zvada, S. P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., . . . McIlleron, H. M. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.01964-18DOI: 10.1128/AAC.01964-18
Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies (Conference Paper)
Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Hobson, J., Al-Khouja, A., Curley, P., Meyers, D., Flexner, C., Siccardi, M., . . . Rannard, S. P. (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 10. doi:10.1038/s41467-019-09354-zDOI: 10.1038/s41467-019-09354-z
Kaboggoza, J. P., Wang, X., Neary, M., Ayuso, P., Sekaggya-Wiltshire, C., Nakalema, S., . . . Boffito, M. (2019). A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. OPEN FORUM INFECTIOUS DISEASES, 6(2). doi:10.1093/ofid/ofz035DOI: 10.1093/ofid/ofz035
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals (Journal article)
Cerrone, M., Wang, X., Neary, M., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (2019). Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. CLINICAL INFECTIOUS DISEASES, 68(3), 446-452. doi:10.1093/cid/ciy491DOI: 10.1093/cid/ciy491
Abdullahi, S. T., Olagunju, A., Soyinka, J. O., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2019). Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. British journal of clinical pharmacology. doi:10.1111/bcp.13821DOI: 10.1111/bcp.13821
Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery (Conference Paper)
Elbaz, N., Owen, A., Rannard, S., & McDonald, T. (2019). Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 258. Retrieved from https://www.webofscience.com/
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384DOI: 10.1093/jac/dky384
Olagunju, A., Anweh, D., Okafor, O., Dickinson, L., Richman, D., Owen, A., & Adejuyigbe, E. (2019). Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. doi:10.12688/wellcomeopenres.15072.1DOI: 10.12688/wellcomeopenres.15072.1
2018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro (Journal article)
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482DOI: 10.1021/acs.molpharmaceut.8b00482
Keshavjee, S., Amanullah, F., Cattamanchi, A., Chaisson, R., Dobos, K. M., Fox, G. J., . . . Nahid, P. (2018). Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.. American journal of respiratory and critical care medicine. doi:10.1164/rccm.201806-1053ppDOI: 10.1164/rccm.201806-1053pp
Adegbola, A., Abutaima, R., Olagunju, A., Ijarotimi, O., Siccardi, M., Owen, A., . . . Bolaji, O. (2018). Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(10). doi:10.1128/AAC.01252-18DOI: 10.1128/AAC.01252-18
Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions (Conference Paper)
Hern, F. Y., Tatham, L., Owen, A., & Rannard, S. (2018). Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions. In 256th National Meeting and Exposition of the American-Chemical-Society (ACS) - Nanoscience, Nanotechnology and Beyond Vol. 256. Boston, MA.
Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir (Conference Paper)
Savage, A., Ashcroft, S., Box, H., Sharp, J., Neary, M., Owen, A., & Rannard, S. (2018). Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum (Journal article)
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika-Kibwika, P., . . . Boffito, M. (2018). Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. CLINICAL INFECTIOUS DISEASES, 67(5), 785-790. doi:10.1093/cid/ciy161DOI: 10.1093/cid/ciy161
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004DOI: 10.1016/j.dmpk.2018.01.004
Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2018). Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(8), 937-944. doi:10.5588/ijtld.17.0515DOI: 10.5588/ijtld.17.0515
The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV (Journal article)
Hobson, J. J., Owen, A., & Rannard, S. P. (2018). The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV. NANOMEDICINE, 13(16), 1963-1965. doi:10.2217/nnm-2018-0182DOI: 10.2217/nnm-2018-0182
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications (Journal article)
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18DOI: 10.1128/AAC.00717-18
The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation (Journal article)
Siccardi, M., Rannard, S., & Owen, A. (2018). The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 131, 116-121. doi:10.1016/j.addr.2018.06.016DOI: 10.1016/j.addr.2018.06.016
Pushpakom, S. P., Adaikalakoteswari, A., Owen, A., Back, D. J., Tripathi, G., Kumar, S., . . . Pirmohamed, M. (2018). Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.. Diabetes & vascular disease research, 15(3), 233-242. doi:10.1177/1479164118757924DOI: 10.1177/1479164118757924
Hobson, J., Edwards, S., Slater, R., Martin, P., Owen, A., & Rannard, S. P. (2018). Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems. RSC Advances. doi:10.1039/c8ra01944dDOI: 10.1039/c8ra01944d
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515DOI: 10.1093/jac/dkx515
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17DOI: 10.1128/aac.01909-17
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2018). Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. JOURNAL OF NANOBIOTECHNOLOGY, 16. doi:10.1186/s12951-018-0349-yDOI: 10.1186/s12951-018-0349-y
Rannard, S. P., Owen, A., & Hern, F. (2018). Co-initiated hyperbranched-polydendron buildingblocks for the direct nanoprecipitation ofdendron-directed patchy particles withheterogeneous surface functionality. Polymer Chemistry. doi:10.1039/C8PY00291FDOI: 10.1039/C8PY00291F
Tatham, L., Savage, A. C., Dwyer, A. B., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Maraviroc solid drug nanoparticles with improved oral pharmacokinetics. In CROI. Boston MA.
Tatham, L., Dwyer, A. B., Savage, A. C., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc. In CROI. Boston MA.
Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (n.d.). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.
Neary, M. G., Chappell, C., Scarsi, K., Nakalema, S., Matovu, J., Achilles, S., . . . Lamorde, M. (2018, March 5). CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.. In CROI. Boston, MA, USA.
Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV. (Conference Paper)
Cerrone, M., Xinhu, W., Neary, M. G., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (n.d.). Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.. In CROI. Boston, MA, USA.
Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation. (Conference Paper)
Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.
Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics. (Conference Paper)
Cerrone, M., Alfarisi, O., Neary, M. G., Marzinke, O., Parsons, T., Owen, A., . . . Boffito, M. (n.d.). Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.. In CROI. Boston, MA, USA.
Moss, D. M., Curley, P., Kinvig, H., Hoskins, C., & Owen, A. (2018). The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 12(3), 223-236. doi:10.1080/17474124.2018.1399794DOI: 10.1080/17474124.2018.1399794
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-xDOI: 10.1007/s40262-017-0557-x
Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., . . . Flexner, C. (2018). Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(2), 125-132. doi:10.5588/ijtld.17.0486DOI: 10.5588/ijtld.17.0486
Bakshi, R. P., Tatham, L. M., Savage, A. C., Tripathi, A. K., Mlambo, G., Ippolito, M. M., . . . Shapiro, T. A. (2018). Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nature Communications, 9. doi:10.1038/s41467-017-02603-zDOI: 10.1038/s41467-017-02603-z
Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507DOI: 10.1093/jac/dkx507
Curley, P., Liptrott, N. J., & Owen, A. (2018). Advances in nanomedicine drug delivery applications for HIV therapy. FUTURE SCIENCE OA, 4(1). doi:10.4155/fsoa-2017-0069DOI: 10.4155/fsoa-2017-0069
Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens (Conference Paper)
Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/
Hern, F., Tatham, L., Owen, A., & Rannard, S. (2018). Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions. Retrieved from https://www.webofscience.com/
Olagunju, A., Schipani, A., Bolaji, O., Khoo, S., & Owen, A. (2018). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(1), 165-172. doi:10.1093/jac/dkx334DOI: 10.1093/jac/dkx334
LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS (Conference Paper)
Bakshi, R., Tatham, L., Savage, A., Tripathi, A., Mlambo, G., Ippolito, M., . . . Shapiro, T. (2018). LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 99 (pp. 94). Retrieved from https://www.webofscience.com/
Potential for immune modulation by inhibition of autophagic processes. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2018). Potential for immune modulation by inhibition of autophagic processes.. Poster session presented at the meeting of Nanomedicine's Early Career Researchers Meeting. London.
Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage (Conference Paper)
Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
2017
Pharmacogenetic considerations for HIV treatment in different ethnicities: an update (Journal article)
Neary, M., & Owen, A. (2017). Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(11), 1169-1181. doi:10.1080/17425255.2017.1391214DOI: 10.1080/17425255.2017.1391214
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359DOI: 10.1002/prp2.359
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2017). Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. NANOMEDICINE, 12(17), 2043-2054. doi:10.2217/nnm-2017-0095DOI: 10.2217/nnm-2017-0095
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667DOI: 10.1002/cpt.667
Tatham, L., Savage, A., Rannard, S., & Owen, A. (2017). Maraviroc Solid Drug Nanoparticles with Improved Oral Pharmacokinetics. In British Society for Nanomedicine. Queens University Belfast.
Rajoli, R. K. R., Flexner, C., Owen, A., Donnelly, R., & Siccardi, M. (2017). Transdermal delivery with microneedle patches using in silico modelling. Belfast.
Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., . . . Davies, G. R. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00210-17DOI: 10.1128/AAC.00210-17
Moss, D. M., Domanico, P., Watkins, M., Park, S., Randolph, R., Wring, S., . . . Owen, A. (2017). Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00105-17DOI: 10.1128/AAC.00105-17
Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16DOI: 10.1128/AAC.01776-16
David, C., Ahmed, F., Owen, A., & Liptrott, N. (2017). Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.. Journal of Interdisciplinary Nanomedicine.
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs (Journal article)
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485DOI: 10.1093/jac/dkw485
ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine. (Conference Paper)
Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.
Current Progress in the Pharmacogenetics of Infectious Disease Therapy (Chapter)
Elliot, E., Mahungu, T., & Owen, A. (2017). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES, 2ND EDITION (pp. 435-457). doi:10.1016/B978-0-12-799942-5.00019-6DOI: 10.1016/B978-0-12-799942-5.00019-6
Rosslein, M., Liptrott, N. J., Owen, A., Boisseau, P., Wick, P., & Herrmann, I. K. (2017). Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. NANOTOXICOLOGY, 11(2), 147-149. doi:10.1080/17435390.2017.1279361DOI: 10.1080/17435390.2017.1279361
Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001DOI: 10.1515/ejnm-2017-0001
Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems. (Poster)
David, C., Giardiello, M., Rannard, S. P., Owen, A., & Liptrott, N. J. (2017). Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.. Poster session presented at the meeting of BSNM Early Career Researchers' Meeting. Belfast.
Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens (Conference Paper)
Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16DOI: 10.1128/AAC.01841-16
Bienczak, A., Cook, A., Wiesner, L., Mulenga, V., Kityo, C., Kekitiinwa, A., . . . Denti, P. (2017). Effect of diurnal variation, <i>CYP2B6</i> genotype and age on the pharmacokinetics of nevirapine in African children. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(1), 190-199. doi:10.1093/jac/dkw388DOI: 10.1093/jac/dkw388
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients (Journal article)
Sandkovsky, U., Podany, A. T., Fletcher, C. V., Owen, A., Felton-Coleman, A., Winchester, L. C., . . . Swindells, S. (2017). Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(1), 200-204. doi:10.1093/jac/dkw403DOI: 10.1093/jac/dkw403
Integrated pharmacokinetic modelling for accelerated nanomedicine translation (Journal article)
Siccardi, M., Löffler, B., Balogh, L., & Owen, A. (2017). Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 9(1), 1-3. doi:10.1515/ejnm-2016-0041DOI: 10.1515/ejnm-2016-0041
Long acting injectable formulations of atovaquone for malaria prophylaxis (Conference Paper)
Savage, A., Tatham, L., Bakshi, R., Tripathi, A., Mlambo, G., Shapiro, T., . . . Rannard, S. (2017). Long acting injectable formulations of atovaquone for malaria prophylaxis. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules (Conference Paper)
Hobson, J., Edwards, S., Owen, A., & Rannard, S. (2017). New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum (Conference Paper)
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika, P., . . . Boffito, M. (2017). Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 122). Retrieved from https://www.webofscience.com/
Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines (Conference Paper)
Giardiello, M., McDonald, T., Liptrott, N., Martin, P., Smith, D., Siccardi, M., . . . Rannard, S. (2017). Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot (Conference Paper)
Hobson, J., Curley, P., Al-khouja, A., Meyers, C., Flexner, C., Owen, A., & Rannard, S. (2017). Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES (Conference Paper)
Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.099DOI: 10.1016/j.dmpk.2016.10.099
2016
Computational Predictive Models for Nanomedicine (Chapter)
Siccardi, M., Schipani, A., & Owen, A. (n.d.). Computational Predictive Models for Nanomedicine. In Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production (pp. 379-402). Wiley-VCH Verlag GmbH & Co. KGaA.
Rajoli, R. K. R., Podany, A., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling. Liverpool.
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184DOI: 10.1038/ncomms13184
Curley, P., Siccardi, M., Moss, D. M., & Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8(20), 2125-2134. doi:10.4155/bio-2016-0021DOI: 10.4155/bio-2016-0021
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21DOI: 10.1002/jin2.21
Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma (Journal article)
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2016). Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma. HIV CLINICAL TRIALS, 17(5), 197-203. doi:10.1080/15284336.2016.1210719DOI: 10.1080/15284336.2016.1210719
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.
Abstract (Conference Paper)
Abstract (2016). In Journal of Interdisciplinary Nanomedicine Vol. 1 (pp. 35-82). Wiley. doi:10.1002/jin2.14DOI: 10.1002/jin2.14
Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles (Conference Paper)
Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. In British Society of Nanomedicine Early Career Meeting Vol. 1 (pp. 78). Swansea University. doi:10.1002/jin2.14DOI: 10.1002/jin2.14
Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study (Journal article)
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227DOI: 10.1097/FPC.0000000000000227
Owen, A., & Rannard, S. (2016). Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. ADVANCED DRUG DELIVERY REVIEWS, 103, 144-156. doi:10.1016/j.addr.2016.02.003DOI: 10.1016/j.addr.2016.02.003
Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers (Conference Paper)
Tatham, L., Ford, J., Rogers, H., Rannard, S., & Owen, A. (2016). Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers. In Controlled Release Society Annual Meeting & Exposition. Seattle, Washington.
Tatham, L., Ford, J., Rogers, H., Rannard, S., & Owen, A. (2016). Surface-Dependent Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers. In Controlled Release Society Annual Meeting & Exposition. Seattle, Washington.
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5DOI: 10.1007/s40262-015-0360-5
Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles (Poster)
Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. P. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. Poster session presented at the meeting of Royal Society of Chemistry Early Career Symposium. University of Strathclyde.
David, C. A. W., Owen, A., & Liptrott, N. J. (2016). Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. NANOMEDICINE, 11(11), 1447-1464. doi:10.2217/nnm-2016-0017DOI: 10.2217/nnm-2016-0017
Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis (Journal article)
Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016DOI: 10.2217/pgs-2015-0016
Siccardi, M., Dickinson, L., & Owen, A. (n.d.). Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60, 3838-3839. doi:10.1128/AAC.00094-16DOI: 10.1128/AAC.00094-16
Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review (Chapter)
Owen, A., Rannard, S. P., Bawa, R., & Feng, S. -S. (2016). Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 1223-1237). Retrieved from https://www.webofscience.com/
Giardiello, M., Hatton, F. L., Slater, R. A., Chambon, P., North, J., Peacock, A. K., . . . Rannard, S. P. (2016). Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. Nanoscale, 8(13), 7224-7231. doi:10.1039/c6nr00788kDOI: 10.1039/c6nr00788k
Siccardi, M., Dickinson, L., & Owen, A. (2016). Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). Retrieved from http://gateway.webofknowledge.com/
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake (Journal article)
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425DOI: 10.1093/jac/dkv425
Handbook of Immunological Properties of Engineered Nanomaterials (Chapter)
Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677DOI: 10.1142/9677
Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles (Journal article)
Silva, A. H., Locatelli, C., Filippin-Monteiro, F. B., Martin, P., Liptrott, N. J., Zanetti-Ramos, B. G., . . . Creczynski-Pasa, T. B. (2016). Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. TOXICOLOGY LETTERS, 246, 17-27. doi:10.1016/j.toxlet.2016.01.018DOI: 10.1016/j.toxlet.2016.01.018
Emerging nanomedicine applications and manufacturing: progress and challenges (Journal article)
Sartain, F., Greco, F., Hill, K., Rannard, S., & Owen, A. (2016). Emerging nanomedicine applications and manufacturing: progress and challenges. NANOMEDICINE, 11(6), 577-580. doi:10.2217/nnm.16.17DOI: 10.2217/nnm.16.17
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.
Solid drug nanoparticles: Methods for production and pharmacokinetic benefits (Chapter)
Owen, A., & Rannard, S. P. (2016). Solid drug nanoparticles: Methods for production and pharmacokinetic benefits. In Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications (Vol. 1, pp. 211-232). doi:10.4032/9789814669214DOI: 10.4032/9789814669214
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy. (Conference Paper)
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
Association of SLCO1B1 521T > C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study (Conference Paper)
Gurjar, R., Boffito, M., D'Avolio, A., Schwimmer, C., Yazdanpanah, Y., Doroana, M., . . . Owen, A. (2016). Association of SLCO1B1 521T > C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2016). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of University of Liverpool ITM Research Day. Liverpool.
Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis (Journal article)
Hennig, S., Naiker, S., Reddy, T., Egan, D., Kellerman, T., Wiesner, L., . . . Pym, A. (2016). Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 617-620. doi:10.1128/AAC.01195-15DOI: 10.1128/AAC.01195-15
Intracellular Transport and Unpacking of Polyplex Nanoparticles (Chapter)
Rosenkranz, A. A., Khramtsov, Y. V., Ulasov, A. V., Rodichenko, N., & Sobolev, A. S. (2016). Intracellular Transport and Unpacking of Polyplex Nanoparticles. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 823-843). Retrieved from https://www.webofscience.com/
The Challenge of Regulating Nanomedicine: Key Issues (Chapter)
Bawa, R., Barenholz, Y., & Owen, A. (2016). The Challenge of Regulating Nanomedicine: Key Issues. In NANOMEDICINES: DESIGN, DELIVERY AND DETECTION (Vol. 51, pp. 290-314). Retrieved from https://www.webofscience.com/
Bienczak, A., Cook, A., Wiesner, L., Olagunju, A., Mulenga, V., Kityo, C., . . . Denti, P. (2016). The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 82(1), 185-198. doi:10.1111/bcp.12934DOI: 10.1111/bcp.12934
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV (Journal article)
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1DOI: 10.1007/s40262-014-0227-1
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment (Journal article)
Nelson, A. G., Zhang, X., Ganapathi, U., Szekely, Z., Flexner, C. W., Owen, A., & Sinko, P. J. (2015). Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. JOURNAL OF CONTROLLED RELEASE, 219, 669-680. doi:10.1016/j.jconrel.2015.08.042DOI: 10.1016/j.jconrel.2015.08.042
Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation (Journal article)
Naisbitt, D., Yang, E. L., Alhaidari, M., Berry, N., Lawrenson, A. S., Farrell, J., . . . Park, B. (2015). Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS, 29(18), 2385-2395. doi:10.1097/QAD.0000000000000867DOI: 10.1097/QAD.0000000000000867
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models (Conference Paper)
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Class-specific relative genetic contribution for key antiretroviral drugs (Journal article)
Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207DOI: 10.1093/jac/dkv207
Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles (Journal article)
Martin, P., Giardiello, M., McDonald, T. C., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015). Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. MOLECULAR PHARMACEUTICS, 12(10), 3556-3568. doi:10.1021/acs.molpharmaceut.5b00204DOI: 10.1021/acs.molpharmaceut.5b00204
Considerations for clinically-relevant nanomedicine therapies for chronic diseases (Journal article)
Owen, A., & Rannard, S. (2015). Considerations for clinically-relevant nanomedicine therapies for chronic diseases. NANOMEDICINE, 10(20), 3103-3107. doi:10.2217/nnm.15.135DOI: 10.2217/nnm.15.135
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174DOI: 10.1093/jac/dkv174
Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons (Journal article)
Rogers, H. E., Chambon, P., Auty, S. E. R., Hern, F. Y., Owen, A., & Rannard, S. P. (2015). Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. SOFT MATTER, 11(35), 7005-7015. doi:10.1039/c5sm00673bDOI: 10.1039/c5sm00673b
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156DOI: 10.1002/cpt.156
Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs (Poster)
Savage, A. C., Tatham, L. M., Owen, A., & Rannard, S. P. (2015). Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs. Poster session presented at the meeting of British Society of Nanomedicine Young Researchers Meeting. University of Liverpool.
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317DOI: 10.1093/cid/civ317
Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research (Journal article)
McIlleron, H., Abdel-Rahman, S., Dave, J. A., Blockman, M., & Owen, A. (2015). Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. JOURNAL OF INFECTIOUS DISEASES, 211, S115-S125. doi:10.1093/infdis/jiu600DOI: 10.1093/infdis/jiu600
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study (Journal article)
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
The Application of Nanotechnology to Drug Delivery in Medicine (Chapter)
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5DOI: 10.1016/b978-0-444-62747-6.00007-5
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry (Journal article)
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53DOI: 10.2217/pgs.15.53
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77DOI: 10.2217/NNM.14.77
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976DOI: 10.1093/cid/ciu976
Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics (Journal article)
Tatham, L. M., Rannard, S. P., & Owen, A. (2015). Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. THERAPEUTIC DELIVERY, 6(4), 469-490. doi:10.4155/TDE.15.4DOI: 10.4155/TDE.15.4
No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults (Journal article)
Sirirungsi, W., Urien, S., Harrison, L., Kamkon, J., Tawon, Y., Luekamlung, N., . . . Cressey, T. R. (2015). No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 68(4), E56-E59. doi:10.1097/QAI.0000000000000504DOI: 10.1097/QAI.0000000000000504
Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media (Journal article)
Ford, J., Chambon, P., North, J., Hatton, F. L., Giardiello, M., Owen, A., & Rannard, S. P. (2015). Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. MACROMOLECULES, 48(6), 1883-1893. doi:10.1021/acs.macromol.5b00099DOI: 10.1021/acs.macromol.5b00099
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43DOI: 10.1002/cpt.43
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420DOI: 10.1093/jac/dku420
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2015). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of European Nanomedicine Meeting. Grenoble.
Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium (Journal article)
Hatton, F. L., Tatham, L. M., Tidbury, L. R., Chambon, P., He, T., Owen, A., & Rannard, S. P. (2015). Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. CHEMICAL SCIENCE, 6(1), 326-334. doi:10.1039/c4sc02889aDOI: 10.1039/c4sc02889a
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter (Journal article)
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078DOI: 10.3389/fphar.2015.00078
Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy. (Poster)
David, C., Liptrott, N. J., & Owen, A. (2015). Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.. Poster session presented at the meeting of University of Liverpool Poster Day. Liverpool.
Optimisation of methodology to assess the impact of nanomaterials on autophagy. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2015). Optimisation of methodology to assess the impact of nanomaterials on autophagy.. Poster session presented at the meeting of BSNM Young Researcher Meeting. Liverpool.
Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs (Chapter)
Owen, A., & Curley, P. (2015). Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. In Humanized Mice for HIV Research, 1st Edition. Springer.
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine (Journal article)
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8DOI: 10.1007/s40262-014-0184-8
Utility of kinetic measurement of oxidative stress in nanotoxicological assay development. (Poster)
David, C., Raymant, M. L., Owen, A., & Liptrott, N. J. (2015). Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.. Poster session presented at the meeting of Nanotechnology in Medicine. Manchester.
pH-Responsive hyperbranched-polydendrons for drug delivery applications (Conference Paper)
Rogers, H., Tatham, L., Chambon, P., Owen, A., & Rannard, S. (2015). pH-Responsive hyperbranched-polydendrons for drug delivery applications. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 250. Retrieved from https://www.webofscience.com/
2014
<i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients (Journal article)
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098DOI: 10.1097/FTD.0000000000000098
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312DOI: 10.1093/jac/dku312
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312DOI: 10.1093/jac/dku312
Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix' (Journal article)
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'. Nanomedicine, 9(16), 2467-2479. doi:10.2217/nnm.14.38DOI: 10.2217/nnm.14.38
The application of nanotechnology in medicine: treatment and diagnostics (Journal article)
Owen, A., Dufes, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). The application of nanotechnology in medicine: treatment and diagnostics. NANOMEDICINE, 9(9), 1291-1294. doi:10.2217/NNM.14.93DOI: 10.2217/NNM.14.93
Enabling the genomic revolution in Africa (Journal article)
Rotimi, C. (2014). Enabling the genomic revolution in Africa. SCIENCE, 344(6190), 1346-1348. doi:10.1126/science.1251546DOI: 10.1126/science.1251546
Polydendrons (Patent)
Rannard, S., Owen, A., Rogers, H., Hatton, F., & Southworth, F. (2014, June 13). WO2014199175 A1, Polydendrons.
Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol (Journal article)
Dwyer, A. B., Chambon, P., Town, A., He, T., Owen, A., & Rannard, S. P. (2014). Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol. POLYMER CHEMISTRY, 5(11), 3608-3616. doi:10.1039/c4py00182fDOI: 10.1039/c4py00182f
Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents (Journal article)
Hatton, F. L., Chambon, P., McDonald, T. O., Owen, A., & Rannard, S. P. (2014). Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. CHEMICAL SCIENCE, 5(5), 1844-1853. doi:10.1039/c4sc00360hDOI: 10.1039/c4sc00360h
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2014). Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling. Poster session presented at the meeting of Conference On Retroviruses And Opportunistic Infections. Boston, MA, USA.
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation (Journal article)
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280DOI: 10.1002/adhm.201300280
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients (Journal article)
Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372DOI: 10.1093/jac/dkt372
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073DOI: 10.1097/FPC.0000000000000073
<i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles (Conference Paper)
King, S. C., Oliveira, M., Moisi, D., Brenner, B., Giardiello, M., Rannard, S. P., . . . Geretti, A. M. (2014). <i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles. In ANTIVIRAL THERAPY Vol. 19 (pp. A126). Retrieved from https://www.webofscience.com/
CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. (Journal article)
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.. Ther Drug Monit..
Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014 (Journal article)
Owen, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014. Nanomedicine.
Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy (Journal article)
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2014). Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy. HIV MEDICINE, 15, 53-54. Retrieved from https://www.webofscience.com/
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine (Poster)
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Investigating the interaction of gold nanoparticles with the human immune system (Journal article)
Kendall, E., Liptrott, N., & Owen, A. (2014). Investigating the interaction of gold nanoparticles with the human immune system. SCOTTISH MEDICAL JOURNAL, 59(1), E34. Retrieved from https://www.webofscience.com/
Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration (Poster)
Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents (Journal article)
Boffito, M., Jackson, A., Owen, A., & Becker, S. (2014). New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. DRUGS, 74(1), 7-13. doi:10.1007/s40265-013-0163-7DOI: 10.1007/s40265-013-0163-7
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix' (Journal article)
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (London).
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. (Journal article)
Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.. J Antimicrob Chemother., 69(2), 491-499.
Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir (Conference Paper)
Alvarez, E., Owen, A., Martin Carbonero, L., Siccardi, M., Valencia, E., Moreno, V., . . . Rodriguez-Novoa, S. (2014). Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir. In ANTIVIRAL THERAPY Vol. 19 (pp. A11). Retrieved from https://www.webofscience.com/
Special issue of BJP on Nanomedicine (Journal article)
Owen, A. (2014). Special issue of BJP on Nanomedicine. BRITISH JOURNAL OF PHARMACOLOGY, 171(17), 3961-3962. doi:10.1111/bph.12820DOI: 10.1111/bph.12820
The application of nanotechnology to drug delivery in Medicine (Chapter)
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Owen, A., & Rannard, S. (2014). The application of nanotechnology to drug delivery in Medicine. In P. Dolez (Ed.), Nano Engineering: Global Approaches to Health and Safety Issues (pp. 1-500). Toronto: Elsevier Health Sciences.
The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study (Journal article)
Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2014). The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study. LANCET, 383, 44. Retrieved from https://www.webofscience.com/
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents (Poster)
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
The role of drug transporters in the kidney: lessons from tenofovir (Journal article)
Moss, D. M., Neary, M., & Owen, A. (2014). The role of drug transporters in the kidney: lessons from tenofovir. FRONTIERS IN PHARMACOLOGY, 5. doi:10.3389/fphar.2014.00248DOI: 10.3389/fphar.2014.00248
2013
Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine (Journal article)
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013). Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 6366-6369. doi:10.1128/AAC.01124-13DOI: 10.1128/AAC.01124-13
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225DOI: 10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i> (Journal article)
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13DOI: 10.1128/AAC.01421-13
Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA (Journal article)
Williamson, B., Soars, A. C., Owen, A., White, P., Riley, R. J., & Soars, M. G. (2013). Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. XENOBIOTICA, 43(10), 920-931. doi:10.3109/00498254.2013.776194DOI: 10.3109/00498254.2013.776194
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i> (Journal article)
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>. JOURNAL OF MATERIALS CHEMISTRY B, 1(35), 4455-4465. doi:10.1039/c3tb20543fDOI: 10.1039/c3tb20543f
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67DOI: 10.2217/fvl.13.67
Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy (Journal article)
Geretti, A. M., Fox, Z., Johnson, J. A., Booth, C., Lipscomb, J., Stuyver, L. J., . . . Phillips, A. (2013). Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLOS ONE, 8(7). doi:10.1371/journal.pone.0069266DOI: 10.1371/journal.pone.0069266
Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients (Journal article)
Martin, P., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2013). Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients. MOLECULAR PHARMACEUTICS, 10(7), 2739-2748. doi:10.1021/mp400175nDOI: 10.1021/mp400175n
Predicting intestinal absorption of raltegravir using a population-based ADME simulation (Journal article)
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084DOI: 10.1093/jac/dkt084
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7DOI: 10.1007/s40262-013-0056-7
Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients (Journal article)
Molto, J., Xinarianos, G., Miranda, C., Pushpakom, S., Cedeno, S., Clotet, B., . . . Valle, M. (2013). Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. CLINICAL PHARMACOKINETICS, 52(7), 543-553. doi:10.1007/s40262-013-0057-6DOI: 10.1007/s40262-013-0057-6
ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein (Journal article)
Dickens, D., Owen, A., Alfirevic, A., & Pirmohamed, M. (2013). ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein. PHARMACOGENETICS AND GENOMICS, 23(6), 314-323. doi:10.1097/FPC.0b013e328360d10cDOI: 10.1097/FPC.0b013e328360d10c
Transport of gabapentin by LAT1 (SLC7A5) (Journal article)
Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Raedisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). BIOCHEMICAL PHARMACOLOGY, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022DOI: 10.1016/j.bcp.2013.03.022
Transport of gabapentin by LAT1 (SLC7A5) (Journal article)
Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Rädisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022DOI: 10.1016/j.bcp.2013.03.022
A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp (Journal article)
Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. PLOS ONE, 8(5). doi:10.1371/journal.pone.0064854DOI: 10.1371/journal.pone.0064854
Compositions of Lopinavir and Ritonavir (Patent)
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2013). Compositions of Lopinavir and Ritonavir.
HIV Drug Nanodispersions (Patent)
Rannard, S., Owen, A., Giardiello, M., McDonald, T., Smith, D., & Martin, P. (2013). HIV Drug Nanodispersions.
Nanoparticles Formulation of Lopinavir (Patent)
Rannard, S., Owen, A., Smith, S., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2013). Nanoparticles Formulation of Lopinavir.
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor (Journal article)
Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., & la Porte, C. J. L. (2013). Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. THERAPEUTIC DRUG MONITORING, 35(1), 78-83. doi:10.1097/FTD.0b013e318274197eDOI: 10.1097/FTD.0b013e318274197e
Pushpakom, S. P., Owen, A., Back, D. J., & Pirmohamed, M. (2013). <i>RXR</i> gene variants are associated with HIV lipodystrophy. PHARMACOGENETICS AND GENOMICS, 23(8), 438-441. doi:10.1097/FPC.0b013e328362cfc6DOI: 10.1097/FPC.0b013e328362cfc6
'Research Spotlight: Nanomedicines for HIV therapy' (Journal article)
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). 'Research Spotlight: Nanomedicines for HIV therapy'. Therapeutic Delivery, 4(2), 153.
A multi-system approach assessing the interaction of anticonvulsants with P-gp. (Journal article)
Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A multi-system approach assessing the interaction of anticonvulsants with P-gp.. PloS One, 8(5), e64854.
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles (Conference Paper)
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml (Conference Paper)
Geretti, A. M., Cozzi-Lepri, A., Vitiello, P., King, S., Owen, A., & Phillips, A. (2013). HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml. In ANTIVIRAL THERAPY Vol. 18 (pp. A27). Retrieved from https://www.webofscience.com/
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli (Journal article)
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. Journal of Materials Chemistry B, 1(35), 4455. doi:10.1039/c3tb20543fDOI: 10.1039/c3tb20543f
Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach (Poster)
Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.
Nanomedicines for HIV therapy. (Journal article)
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156DOI: 10.4155/tde.12.156
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching (Journal article)
Giardiello, M., McDonald, T. O., Lee, J. -S., Roberts, A. D., Owen, A., & Rannard, S. P. (2013). Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. GREEN CHEMISTRY, 15(6), 1590-1599. doi:10.1039/c3gc40573gDOI: 10.1039/c3gc40573g
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies (Journal article)
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231DOI: 10.1097/QAI.0b013e3182737231
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Poster)
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles (Journal article)
Giardiello, M., McDonald, T. O., Martin, P., Owen, A., & Rannard, S. P. (2012). Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles. JOURNAL OF MATERIALS CHEMISTRY, 22(47), 24744-24752. doi:10.1039/c2jm34974dDOI: 10.1039/c2jm34974d
Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor (Journal article)
Maguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T., Doherty, D., . . . Thompson, P. (2012). Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 364(1-2), 54-64. doi:10.1016/j.mce.2012.08.007DOI: 10.1016/j.mce.2012.08.007
Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339DOI: 10.7448/IAS.15.6.18339
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model (Journal article)
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61DOI: 10.1038/clpt.2012.61
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding (Journal article)
Olagunju, A., Owen, A., & Creesey, T. R. (2012). Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. PHARMACOGENOMICS, 13(13), 1501-1522. doi:10.2217/PGS.12.138DOI: 10.2217/PGS.12.138
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095DOI: 10.3851/IMP2095
Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems (Journal article)
McDonald, T. O., Martin, P., Patterson, J. P., Smith, D., Giardiello, M., Marcello, M., . . . Rannard, S. (2012). Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. ADVANCED FUNCTIONAL MATERIALS, 22(12), 2469-2478. doi:10.1002/adfm.201103059DOI: 10.1002/adfm.201103059
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i> (Journal article)
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11DOI: 10.1128/AAC.06407-11
\Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals (Journal article)
Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Owen, A., . . . Csajka, C. (2012). \Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 2959-2966. doi:10.1128/AAC.05424-11DOI: 10.1128/AAC.05424-11
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting (Journal article)
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50aDOI: 10.1097/FTD.0b013e31824aa50a
Lamotrigine is a substrate for OCT1 in brain endothelial cells (Journal article)
Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032DOI: 10.1016/j.bcp.2011.12.032
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies (Journal article)
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491DOI: 10.1093/jac/dkr491
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies (Journal article)
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 675-680. doi:10.1093/jac/dkr491DOI: 10.1093/jac/dkr491
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg (Journal article)
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 671-674. doi:10.1093/jac/dkr493DOI: 10.1093/jac/dkr493
Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy (Journal article)
Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2012). Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 54(5), 724-732. doi:10.1093/cid/cir936DOI: 10.1093/cid/cir936
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82eDOI: 10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82eDOI: 10.1097/fpc.0b013e32834dd82e
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (Journal article)
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Investigation of the potential interactions of efavirenz with the GABAa receptor (Poster)
Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.
Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg. (Journal article)
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.. Journal of Antimicrobial Chemotherapy, 67, 671-674.
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL (Journal article)
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Edwards, D., . . . Back, D. (2012). PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL. CLINICAL PHARMACOLOGY & THERAPEUTICS, 91, S104. Retrieved from https://www.webofscience.com/
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals (Journal article)
Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Boffito, M., . . . Csajka, C. (2012). Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 56, 2959-2966.
Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation (Journal article)
Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 244. Retrieved from https://www.webofscience.com/
Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation (Conference Paper)
Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. In 244th ACS National Meeting & Exposition (pp. COLL-196). Philadelphia: ACS.
2011
IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients (Journal article)
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441cDOI: 10.1097/QAI.0b013e318236441c
Current Progress in the Pharmacogenetics of Infectious Disease Therapy (Chapter)
Mahungu, T., & Owen, A. (2011). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES (pp. 555-578). doi:10.1016/B978-0-12-384890-1.00020-0DOI: 10.1016/B978-0-12-384890-1.00020-0
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy (Journal article)
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10(1). doi:10.1186/1476-4598-10-37DOI: 10.1186/1476-4598-10-37
Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens (Journal article)
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272DOI: 10.1093/jac/dkr272
The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications (Journal article)
Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4122-4127. doi:10.1128/AAC.01833-10DOI: 10.1128/AAC.01833-10
Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (Journal article)
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087DOI: 10.1093/jac/dkr087
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein (Journal article)
Vogler, M., Dickens, D., Dyer, M. J. S., Owen, A., Pirmohamed, M., & Cohen, G. M. (2011). The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 408(2), 344-349. doi:10.1016/j.bbrc.2011.04.043DOI: 10.1016/j.bbrc.2011.04.043
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy (Journal article)
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. MOLECULAR CANCER, 10. doi:10.1186/1476-4598-10-37DOI: 10.1186/1476-4598-10-37
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008) (Journal article)
Garcia-Diaz, A., Lok, C. B., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2011). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(3), 688. doi:10.1093/jac/dkq534DOI: 10.1093/jac/dkq534
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? (Journal article)
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 7(3), 341-352. doi:10.1517/17425255.2011.553600DOI: 10.1517/17425255.2011.553600
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort (Journal article)
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800DOI: 10.1371/journal.pone.0016800
Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i> (Journal article)
Chaijaroenkul, W., Ward, S. A., Mungthin, M., Johnson, D., Owen, A., Bray, P. G., & Na-Bangchang, K. (2011). Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i>. MALARIA JOURNAL, 10. doi:10.1186/1475-2875-10-42DOI: 10.1186/1475-2875-10-42
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10DOI: 10.1128/AAC.00623-10
Adipogenic gene variants in patients with HIV-associated lipodystrophy (Journal article)
Pushpakom, S. P., Owen, A., Vilar, F. J., Castro, H., Dunn, D. T., Back, D. J., & Pirmohamed, M. (2011). Adipogenic gene variants in patients with HIV-associated lipodystrophy. PHARMACOGENETICS AND GENOMICS, 21(2), 76-83. doi:10.1097/FPC.0b013e328342a917DOI: 10.1097/FPC.0b013e328342a917
Compositions of Lopinavir & Ritonavir (Patent)
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2011). Compositions of Lopinavir & Ritonavir.
HIV Drug Nanodispersions (Patent)
Rannard, S., Owen, A., McDonald, T., Smith, D., Giardiello, M., & Martin, P. (2011). HIV Drug Nanodispersions.
Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies (Conference Paper)
McDonald, T. O., Giardielo, M., Smith, D., Martin, P., Owen, A., & Rannard, S. P. (2011). Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies. In 2nd Nano Today Conference (pp. 1). Waikoloa: Nano Today.
Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems (Conference Paper)
McDonald, T., Martin, P., Giardiello, M., Smith, D., Owen, A., & Rannard, S. (2011). Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems. In Nano Today (pp. 1). Waikoloa: Nano Today.
Nanoparticles Formulation of Lopinavir (Patent)
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2011). Nanoparticles Formulation of Lopinavir.
Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy (Journal article)
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10, 37.
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications (Journal article)
Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother, 55(9), 4122-4127.
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? (Journal article)
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. Expert Opinion on Drug Metabolism and Toxicology.
2010
Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism (Journal article)
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efbDOI: 10.1097/FPC.0b013e3283402efb
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10DOI: 10.1128/aac.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10DOI: 10.1128/AAC.00781-10
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort (Journal article)
Carr, D. F., la Porte, C. J. L., Pirmohamed, M., Owen, A., & Cortes, C. P. (2010). Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(9), 1889-1893. doi:10.1093/jac/dkq260DOI: 10.1093/jac/dkq260
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms (Journal article)
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02dDOI: 10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02dDOI: 10.1097/fpc.0b013e328335b02d
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS (Conference Paper)
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells (Journal article)
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. ACTA PHARMACOLOGICA SINICA, 31(1), 51-65. doi:10.1038/aps.2009.187DOI: 10.1038/aps.2009.187
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens (Conference Paper)
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2 (Conference Paper)
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes (Journal article)
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. BRITISH JOURNAL OF PHARMACOLOGY, 159(2), 484-493. doi:10.1111/j.1476-5381.2009.00552.xDOI: 10.1111/j.1476-5381.2009.00552.x
2009
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335DOI: 10.1093/jac/dkp335
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.
Nanomedicine: Not a case of "One size fits all" (Journal article)
Rannard, S., & Owen, A. (2009). Nanomedicine: Not a case of "One size fits all". NANO TODAY, 4(5), 382-384. doi:10.1016/j.nantod.2009.07.002DOI: 10.1016/j.nantod.2009.07.002
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.xDOI: 10.1111/j.1365-2125.2009.03462.x
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC (Journal article)
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz (Journal article)
Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78DOI: 10.1038/clpt.2009.78
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507DOI: 10.1086/598507
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (Journal article)
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.xDOI: 10.1111/j.1468-1293.2008.00689.x
<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa (Journal article)
Alker, A. P., Juliano, J. J., & Meshnick, S. R. (2009). <i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(4), 1722. doi:10.1128/AAC.01427-08DOI: 10.1128/AAC.01427-08
The impact of pharmacogenetics on HIV therapy (Journal article)
Mahungu, T. W., Johnson, M. A., Owen, A., & Back, D. J. (2009). The impact of pharmacogenetics on HIV therapy. INTERNATIONAL JOURNAL OF STD & AIDS, 20(3), 145-151. doi:10.1258/ijsa.2008.008369DOI: 10.1258/ijsa.2008.008369
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives (Chapter)
Vandekerckhove, L. P. R., Christ, F., Debyser, Z., Owen, A., Back, D., Voet, A., . . . Vogelaers, D. (2009). Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. In ANTIVIRAL RESEARCH: STRATEGIES IN ANTIVIRAL DRUG DISCOVERY (pp. 71-+). Retrieved from https://www.webofscience.com/
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study (Journal article)
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry (Journal article)
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010DOI: 10.1016/j.jim.2008.09.010
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (Journal article)
Garcia-Diaz, A., Blok, C., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2008). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1188-1190. doi:10.1093/jac/dkn374DOI: 10.1093/jac/dkn374
<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure (Journal article)
Ochong, E., Bell, D. J., Johnson, D. J., D'Alessandro, U., Mulenga, M., Muangnoicharoen, S., . . . Owen, A. (2008). <i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 3883-3888. doi:10.1128/AAC.00431-08DOI: 10.1128/AAC.00431-08
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir (Journal article)
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304DOI: 10.1086/592304
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir (Journal article)
Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320DOI: 10.1038/bjp.2008.320
Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex (Journal article)
Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex. Molecular Pharmacology, 73(5), 1347-1355. doi:10.1124/mol.108.045120DOI: 10.1124/mol.108.045120
Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex (Journal article)
Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex. MOLECULAR PHARMACOLOGY, 73(5), 1347-1355. doi:10.1124/mol.108.045120DOI: 10.1124/mol.108.045120
Pharmacogenetics of antiretroviral agents (Journal article)
Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4DOI: 10.1097/COH.0b013e3282f7cda4
Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors (Journal article)
Johnson, D. J., Owen, A., Plant, N., Bray, P. G., & Ward, S. A. (2008). Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(4), 1438-1445. doi:10.1128/AAC.01392-07DOI: 10.1128/AAC.01392-07
Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients (Journal article)
Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029DOI: 10.1093/jac/dkn029
Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells (Journal article)
Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. BRITISH JOURNAL OF PHARMACOLOGY, 153(4), 805-819. doi:10.1038/sj.bjp.0707601DOI: 10.1038/sj.bjp.0707601
Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>. (Conference Paper)
Biagini, G. A., Fisher, N., Berry, N., Stocks, P., Meunier, B., Bray, P. G., . . . Ward, S. A. (2008). Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>.. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S41). Retrieved from https://www.webofscience.com/
Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors? (Conference Paper)
Johnson, D. J., Owen, A., Plant, N., & Ward, S. A. (2008). Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors?. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S39). Retrieved from https://www.webofscience.com/
TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i> (Conference Paper)
Ochong, E., Salcedo, E., Bray, P., Ward, S., & Owen, A. (2008). TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i>. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 79 (pp. 302). Retrieved from https://www.webofscience.com/
2007
Tacrine-induced liver damage: an analysis of 19 candidate genes (Journal article)
Alfirevic, A., Mills, T., Carr, D., Barratt, B. J., Jawaid, A., Sherwood, J., . . . Pirmohamed, M. (2007). Tacrine-induced liver damage: an analysis of 19 candidate genes. PHARMACOGENETICS AND GENOMICS, 17(12), 1091-1100. doi:10.1097/FPC.0b013e3282f1f12bDOI: 10.1097/FPC.0b013e3282f1f12b
Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes (Journal article)
Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353DOI: 10.1093/jac/dkm353
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification (Journal article)
Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281DOI: 10.1093/jac/dkm281
Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects (Journal article)
Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230DOI: 10.1093/jac/dkm230
Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i> (Journal article)
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/
Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene (Journal article)
Kitteringham, N. R., Palmer, L., Owen, A., Lian, L. -Y., Jenkins, R., Dowdall, S., . . . Goldring, C. E. (2007). Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1770(8), 1240-1247. doi:10.1016/j.bbagen.2007.05.001DOI: 10.1016/j.bbagen.2007.05.001
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein (Journal article)
Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001DOI: 10.1016/j.tube.2006.12.001
Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART (Journal article)
Liptrott, N., Mahungu, T., Youle, M., Johnson, M., Smith, C., Back, D., . . . Owen, A. (2007). Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 452. Retrieved from http://www.retroconference.org/2007/Abstracts/29534.htm
TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure (Journal article)
Hartkoorn, R., Chandler, B., Owen, A., Ward, S., Squire, B., Back, D., & Khoo, S. (2007). TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 854. Retrieved from http://www.retroconference.org/2007/Abstracts/28849.htm
The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics (Journal article)
Mahungu, T., Khoo, S., Smith, C., Youle, M., Johnson, M., Back, D., & Owen, A. (2007). The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 552. Retrieved from http://www.retroconference.org/2007/Abstracts/28960.htm
2006
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug (Journal article)
Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189DOI: 10.1136/ard.2005.049189
Pharmacogenetics of HIV therapy (Journal article)
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57DOI: 10.1097/01.fpc.0000236338.41799.57
The impact of host pharmacogenetics on antiretroviral drug disposition. (Journal article)
Owen, A. (2006). The impact of host pharmacogenetics on antiretroviral drug disposition.. Current infectious disease reports, 8(5), 401-408. doi:10.1007/s11908-006-0052-2DOI: 10.1007/s11908-006-0052-2
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements (Journal article)
Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2006). Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 62(2), 237-242. doi:10.1111/j.1365-2125.2006.02587.xDOI: 10.1111/j.1365-2125.2006.02587.x
Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance (Journal article)
Leschziner, G., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. PHARMACOGENETICS AND GENOMICS, 16(6), 439-450. doi:10.1097/01.fpc.0000197467.21964.67DOI: 10.1097/01.fpc.0000197467.21964.67
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals (Journal article)
Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006DOI: 10.2165/00003088-200645020-00006
Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes (Journal article)
Goldring, C. E. P., Kitteringham, N. R., Jenkins, R., Lovatt, C. A., Randle, L. E., Abdullah, A., . . . Park, B. K. (2006). Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 290(1), C104-C115. doi:10.1152/ajpcell.00133.2005DOI: 10.1152/ajpcell.00133.2005
Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance (Journal article)
Leschziner, G. D., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenetics and Genomics, 16(6), 439-450.
Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin (Journal article)
Martin, P., Riley, R., Khoo, S., Back, D., & Owen, A. (2006). Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 567.
Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6 (Journal article)
Owen, A., Cook, C., Liptrott, N., Khoo, S., & Back, D. (2006). Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 765.
The assessment of multi-locus gene effects upon lopinavir pharmacokinetics (Journal article)
Owen, A., Mahungu, T., Cook, C., Youle, M., Johnson, M., Back, D., & Khoo, S. (2006). The assessment of multi-locus gene effects upon lopinavir pharmacokinetics. Eighth International Congress on Drug Therapy in HIV Infection, November, Glasgow, UK., N/A, Abstract PL5.4.
2005
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40DOI: 10.1097/01.aids.0000194793.36175.40
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272DOI: 10.1124/jpet.105.086272
The implications of P-glycoprotein in HIV: friend or foe? (Journal article)
Owen, A., Chandler, B., & Back, D. J. (2005). The implications of P-glycoprotein in HIV: friend or foe?. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 19(3), 283-296. doi:10.1111/j.1472-8206.2005.00324.xDOI: 10.1111/j.1472-8206.2005.00324.x
Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver (Journal article)
Owen, A., Goldring, C., Morgan, P., Chadwick, D., Park, B. K., & Pirmohamed, M. (2005). Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 59(3), 365-370. doi:10.1111/j.1365-2125.2005.02229.xDOI: 10.1111/j.1365-2125.2005.02229.x
Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals (Journal article)
Chandler, B., Khoo, S., Detsika, M., Walsh, T., Williams, J., Back, D., & Owen, A. (2005). Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 665.
Host determinants of antiretroviral drug activity (Journal article)
Boffito, M., Alan, W., & Owen, A. (2005). Host determinants of antiretroviral drug activity. CURRENT OPINION IN INFECTIOUS DISEASES, 18(6), 543-549. doi:10.1097/01.qco.0000191507.48481.10DOI: 10.1097/01.qco.0000191507.48481.10
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine (Journal article)
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.
Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines (Journal article)
Martin, P., Owen, A., Back, D., & Riley, R. (2005). Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines. DMDG Open Meeting, N/A(7-9 Se), N/A.
Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes (Journal article)
Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2005). Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes. Toxicology, 213(3), 261-262.
Mitochondria are sensors for HIV drugs (Journal article)
Petit, F., Fromenty, B., Owen, A., & Estaquier, J. (2005). Mitochondria are sensors for HIV drugs. TRENDS IN PHARMACOLOGICAL SCIENCES, 26(5), 258-264. doi:10.1016/j.tips.2005.03.006DOI: 10.1016/j.tips.2005.03.006
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP (Journal article)
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458
P-Glycoprotein and MRP1 Interactions with Rifampicin (Journal article)
Hartkoorn, R., Waitt, C., Chaponda, M., Davies, G., Chandler, B., Owen, A., . . . Khoo, S. (2005). P-Glycoprotein and MRP1 Interactions with Rifampicin. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 666.
Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype (Journal article)
Owen, A., Almond, L., Hartkoorn, R., Walsh, T., Youle, M., Bonington, A., . . . Khoo, S. (2005). Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 650.
The Implications of P-glycoprotein: Friend or Foe? (Journal article)
Owen, A., Chandler, B., & Back, D. (2005). The Implications of P-glycoprotein: Friend or Foe?. Fundamentals of Clinical Pharmacology, 19, 238-296.
The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals (Journal article)
Dickinson, L., Back, D., Chandler, B., Owen, A., Khoo, S., Pozniak, A., & Boffito, M. (2005). The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. 6th International Workshop on Clinical Pharmacology of HIV Therapy, N/A(April), Abstract 9.
2004
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004DOI: 10.1128/JVI.78.21.12022-12029.2004
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/
Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression (Journal article)
Singh, D., Alexander, J., Owen, A., Rustom, R., Bone, M., Hammad, A., . . . Pirmohamed, M. (2004). Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. TRANSPLANTATION, 77(4), 557-561. doi:10.1097/01.TP.0000114594.21317.A5DOI: 10.1097/01.TP.0000114594.21317.A5
-glycoprotein and outcome following lung transplantation (Journal article)
Fildes, J. E., Thekkudan, J., Guntamadugu, R., Owen, A., Singh, D., Yonan, N., & Leonard, C. T. (2004). -glycoprotein and outcome following lung transplantation. The International Society for Heart and Lung Transplantation 24th Annual Meeting and Scientific Sessions, N/A(21-24), N/A.
Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells (Journal article)
Chandler, B., Owen, A., Bray, P. G., Ward, S. A., Back, D. J., & Khoo, S. H. (2004). Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells. XV International AIDS Conference, N/A(11-18), N/A.
Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype (Journal article)
Owen, A., Chandler, B., Walsh, T., Williams, J., Penny, M., Back, D., & Khoo, S. (2004). Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype. Meeting on Pharmacogenomics, N/A(Novemb), 90.
Detection of Minority Strains of HIV Harbouring Drug Resistance (Journal article)
Detsika, M., Winstanley, C., Owen, A., Cane, P., Khoo, S., Back, D., & Hart, C. (2004). Detection of Minority Strains of HIV Harbouring Drug Resistance. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, N/A(30 Oct), N/A.
Development of doxycycline-regulatable gene expression in hepatoma cells (Journal article)
Goldring, C., Kitteringham, N., Lovatt, C., Jenkins, R., Randle, L., Abdullah, A., . . . Park, K. (2004). Development of doxycycline-regulatable gene expression in hepatoma cells. Joint meeting of the BPS/BTS. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.
Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype (Journal article)
Chandler, B., Owen, A., Back, D. J., & Khoo, S. H. (2004). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.
Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents (Journal article)
Janneh, O., Owen, A., Hartkoorn, R. C., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents. BSAC Spring Meeting 2004 in collaboration with the Society of Pharmaceutical Medicine, N/A(2-3 Ma), N/A.
Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1 (Journal article)
Owen, A., Chandler, B., Back, D., & Khoo, S. H. (2004). Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1. Antiviral Therapy, 9(5), 819-821.
Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs. Microsomes and Drug Oxidations, N/A(4-9 Ju), N/A.
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 (Journal article)
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.
In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein (Journal article)
Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein. XV International AIDS Conference, N/A(11-18), N/A.
Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes (Journal article)
Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2004). Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.
Intracellular pharmacokinetics of antiretroviral agents. (Journal article)
Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.
Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters (Journal article)
Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.
The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study (Journal article)
Owen, A., Fox, Z., Almond, L., Dragsted, U. B., Youle, M., Lundgren, J., . . . On behalf of the MaxCmin1 Steering Committee. (2004). The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.
The interaction between active drug transporters and rifampicin accumulation (Journal article)
Hartkoorn, R. C., Janneh, O., Owen, A., Davies, G. R., Chandler, R. J., Khoo, S., & Back, D. J. (2004). The interaction between active drug transporters and rifampicin accumulation. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.
2003
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines (Journal article)
Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024DOI: 10.1097/00002030-200310170-00024
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro (Journal article)
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001DOI: 10.1097/00126334-200308150-00001
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)
Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4DOI: 10.1016/S0022-1759(02)00509-4
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells (Journal article)
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902DOI: 10.1086/367902
The mechanisms that control intracellular penetration of the HIV protease inhibitors (Journal article)
Hoggard, P. G., & Owen, A. (2003). The mechanisms that control intracellular penetration of the HIV protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 51(3), 493-496. doi:10.1093/jac/dkg137DOI: 10.1093/jac/dkg137
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets (Journal article)
Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539
Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells. (Journal article)
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells.. Journal of Infectious Diseases, 18(5), 874-875.
Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype (Journal article)
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2003). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.
Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression (Journal article)
Owen, A., Park, B. K., & Pirmohamed, M. (2003). Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.
Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes (Journal article)
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2003). Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, N/A(July 8), N/A.
Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect (Journal article)
Owen, A., Janneh, O., Hartkoorn, R., Chandler, R., Back, D. J., & Khoo, S. H. (2003). Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect. Federation of Infection Societies Tenth Anniversary Conference, N/A(Novemb), N/A.
The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers (Journal article)
Maher, B., Hoggard, P. G., Chandler, B., Meaden, E. R., Owen, A., Back, D. J., . . . Pirmohamed, M. (2003). The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 524a.
The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics. (Journal article)
Owen, A., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics.. 8th European ISSX meeting, N/A(Apr 27), Abstract 307.
The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines. (Journal article)
Owen, A., Hoggard, P. G., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines.. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 149.
The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. (Journal article)
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S. H., & Back., D. J. (2003). The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.. Journal of Acquired Immune Deficiency Syndromes, 33(5), 551-556.
2002
Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing (Journal article)
Almond, L. M., Chandler, B., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2002). Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing. XIV International AIDS conference, N/A(7-12 J), N/A.
In-vitro Antiretroviral Activity of Antimalarial Agents. (Journal article)
Owen, A., Hoggard, P. G., Bray, P. G., Ward, S. A., Khoo, S. H., Hart, C. A., & Back, D. J. (2002). In-vitro Antiretroviral Activity of Antimalarial Agents.. Sixth International Congress on Drug Therapy in HIV Infection, N/A(17-21), N/A.
Induction of P-glycoprotein in PBMCs in vitro (Journal article)
Chandler, B., Ford, J., Owen, A., Khoo, S. H., & Back, D. J. (2002). Induction of P-glycoprotein in PBMCs in vitro. XIV International AIDS conference, N/A(7-12 J), N/A.
Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression (Journal article)
Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2002). Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.
The role of drug transporters in HIV treatment failure (Journal article)
Owen, A., Hoggard, P. G., & Khoo, S. (2002). The role of drug transporters in HIV treatment failure. HIV and AIDS current trends, 8, 11-12.
2001
LC determination of carbamazepine in murine brain (Journal article)
Owen, A., Tettey, J. N., Morgan, P., Pirmohamed, M., & Park, B. K. (2001). LC determination of carbamazepine in murine brain. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 26(4), 573-577. doi:10.1016/S0731-7085(01)00477-0DOI: 10.1016/S0731-7085(01)00477-0
Carbamazepine is not a substrate for P-glycoprotein (Journal article)
Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2001). Carbamazepine is not a substrate for P-glycoprotein. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 345-349. doi:10.1046/j.1365-2125.2001.01359.xDOI: 10.1046/j.1365-2125.2001.01359.x
2000
Is Carbamazepine a Substrate for P-glycoprotein? (Journal article)
Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is Carbamazepine a Substrate for P-glycoprotein?. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.
Is carbamezapine a substrate for P-glycoprotein? (Conference Paper)
Owen, A., Pirmohamed, M., Tettey, J., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is carbamezapine a substrate for P-glycoprotein?. In British Journal of Clinical Pharmacology Vol. 50 (pp. 387).
1999
Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy (Journal article)
Owen, A., Pirmohamed, M., Morgan, P., Chadwick, D., & Park, B. K. (1999). Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy. Pfizer Poster Symposium, N/A(N/A), N/A.
